DSIP vs trazodone: comparing the evidence for sleep

Last updated 2026-07-26

What are DSIP and trazodone, and are they even in the same category?

No, and this comparison trips people up for exactly that reason. Trazodone is a synthetic antidepressant, a triazolopyridine compound, that the FDA approved in 1981 under the brand name Desyrel for major depressive disorder ^[1]. It's never been FDA-approved for insomnia, but doctors have written off-label prescriptions for sleep for decades, usually at doses far below the antidepressant range. DSIP (delta sleep-inducing peptide) is a nonapeptide first isolated from rabbit brain venous blood in the 1970s by Swiss researchers studying sleep-related electrical activity ^[2]. It was never developed into an approved drug anywhere. It exists today as a research chemical sold for lab and self-experimentation use, not as a licensed pharmaceutical. So the honest framing is: trazodone is an approved drug used off-label for sleep, with real prescribing guidelines and monitoring. DSIP is an unapproved peptide with a thin, old, and mostly non-human evidence base. If you're choosing between them as sleep aids, you're choosing between something your doctor can legally prescribe and monitor, and something that sits outside that system entirely. For background on what DSIP's research record actually contains, see our DSIP evidence overview.

What does the human evidence for DSIP actually show?

It's thin, old, and mixed. Most of the human DSIP trials date from the late 1970s through the early 1990s, involved small samples (often under 20 subjects), and produced inconsistent results on sleep architecture. One frequently cited human study is Schneider-Helmert (1985), which looked at DSIP administration in patients with chronic sleep disturbances and reported some improvement in subjective sleep quality but inconsistent effects on objective polysomnography measures ^[3]. A review by Graf and Kastin (1986) summarizing the DSIP literature to that point described effects on sleep as variable across studies and noted the peptide's mechanism was still not well understood ^[4]. Critically, a lot of the frequently cited DSIP work on stress resilience, opioid withdrawal, and stress hormone modulation comes from animal models (rats, rabbits) or small non-sleep human pilot studies, not controlled human insomnia trials. When a source touts DSIP's effect on 'stress' or 'ACTH suppression,' check whether that's a rodent finding before assuming it applies to a person trying to sleep better. Nobody has run a modern, adequately powered, placebo-controlled human trial of DSIP for insomnia using current polysomnography and actigraphy standards. That trial doesn't exist. What exists is a scattered mid-20th-century literature that suggested a signal worth following up on, and then the follow-up largely stopped.

What does the human evidence for trazodone show?

Trazodone has a much larger and more recent human evidence base, though it's still officially off-label for insomnia. A commonly cited placebo-controlled trial, Roth et al. (2011), tested trazodone 50mg in adults with primary insomnia and found improvements in subjective and polysomnographic sleep measures at some endpoints, though effects were modest and not uniformly sustained across the study period ^[5]. A broader review in the journal Sleep Medicine Reviews (Mendelson, 2005) examined trazodone's use for insomnia and concluded it had 'been used extensively' off-label despite limited placebo-controlled evidence, and cautioned that its efficacy data for chronic insomnia specifically remained weaker than for its approved indication of depression ^[6]. The American Academy of Sleep Medicine's 2017 clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults did not recommend trazodone as a first-line agent, citing insufficient evidence, though it acknowledged trazodone is commonly prescribed anyway . So trazodone isn't a home run either. It's an approved drug being used off-label, with real but imperfect trial data, and clinical guidelines that stop short of endorsing it as first-choice. That's a meaningfully stronger evidence position than DSIP's, but it's not the slam-dunk the frequency of trazodone prescriptions might suggest.

DSIP vs trazodone: side-by-side comparison

How do the side effect profiles compare?

Trazodone's side effects are well documented because it has been prescribed to millions of patients for depression and, off-label, for insomnia over more than four decades. Common effects include daytime sedation and grogginess, dizziness, dry mouth, and orthostatic hypotension (a drop in blood pressure on standing). A rare but serious effect is priapism, a prolonged and potentially damaging erection, which has been documented in case reports and is included in prescribing information as a specific warning. DSIP's side effect profile is much less clear, precisely because the human trial base is so small and old. Some of the mid-century studies reported no significant adverse events at the doses tested, but sample sizes were tiny and monitoring standards from the 1980s don't match what a modern trial would require. There is no large-scale human safety database for DSIP the way there is for an approved drug. That absence of documented harm is not the same as evidence of safety. It just means nobody has looked hard enough, in a large enough group, for long enough. For a fuller rundown of what is and isn't known, see DSIP peptide side effects.

Is DSIP a legal or medically supervised alternative to trazodone?

Not in the way trazodone is. Trazodone requires a prescription, which means a physician evaluates you, sets a dose, and can monitor for interactions or side effects over time. That's a real safety backstop that DSIP, sold as a research compound, does not come with in the same form. DSIP is not FDA-approved for human use, and in the US it is generally sold labeled 'for research use only,' meaning it is not intended for human consumption or clinical treatment under that labeling. That doesn't make possessing it illegal in most cases, but it does mean nobody, chemist or physician, is legally structured to sign off on your dosing, monitor your response, or take clinical responsibility for outcomes. If you're pursuing DSIP anyway for research or self-experimentation, working from a provider-reviewed source and understanding the DSIP dosage landscape and injection technique matters more, not less, given the lack of clinical infrastructure around it.

Which one has better data on stress and cortisol, more than sleep?

This is where a lot of DSIP marketing overreaches. DSIP earned its early research interest partly because some animal studies suggested it modulated the stress hormone axis, including effects on ACTH and cortisol release, in rats and rabbits under stress conditions. Those are real findings, but they're preclinical. They were not run in people struggling with everyday stress or insomnia, and they don't establish that DSIP lowers cortisol or blunts stress responses in humans at any particular dose. Trazodone's stress-adjacent data is different in kind: it's an antidepressant with known effects on serotonergic signaling in humans, backed by the same depression trials that led to its 1981 FDA approval ^[1]. That's a much more direct human evidence base for how it affects mood-related neurochemistry, even though its off-label insomnia use is separately debated. Neither drug has a clean 'reduces cortisol in stressed humans, proven' trial. But trazodone at least has the underlying human pharmacology nailed down. DSIP's human mechanism, per the Graf and Kastin review, was still not well understood as of the 1980s literature ^[4], and not much has changed since.

How do the two compare on dosing and administration?

Trazodone comes as an oral tablet, typically dosed at 25 to 100mg at bedtime for off-label insomnia use, well below the 150-400mg+ range used for depression ^[6]. That range is drawn from clinical literature and prescriber practice, not a formal FDA insomnia label, since none exists. DSIP has no equivalent standardized human dosing because it was never brought through the approval pipeline that would establish one. Doses used in the old human trials varied by study and route (some intravenous, some other parenteral routes), and modern research-use protocols draw on that scattered literature rather than a single accepted standard. Anyone looking at DSIP dosing today is working from historical study doses and current supplier guidance, not an FDA label. Our DSIP dosage guide and dosage calculator walk through how those historical protocols translate into commonly discussed ranges, but be clear-eyed that 'commonly discussed' isn't the same as 'clinically established.'

Which is actually cheaper and easier to access?

Trazodone is generic and typically inexpensive, often a few dollars per month with a prescription discount card or standard insurance copay, though exact cost depends on pharmacy, insurance status, and dose. It requires a doctor's visit or telehealth prescription, which is a real access step but a well-worn one; nearly every primary care physician has prescribed it. DSIP has no insurance angle at all since it's not an approved drug. Pricing varies widely by supplier and purity, and quality control is inconsistent across the research chemical market, meaning two vials labeled identically can differ in actual peptide content. If you're evaluating suppliers, purity documentation and third-party testing matter enormously, more than they would for a regulated pharmaceutical where the FDA and generic manufacturing standards already do that work for you. See buy DSIP for what a provider-reviewed sourcing process should look like, and treat any supplier that won't share a certificate of analysis as a pass.

So which one should you actually use for sleep?

If you need something for sleep tonight and want a human evidence base, a prescriber conversation, and monitored dosing, trazodone is the more defensible clinical choice, even though it's off-label and even the American Academy of Sleep Medicine stops short of recommending it first-line . That's a real caveat, not a dismissal. Ask your prescriber about alternatives too; trazodone isn't the only off-label option and isn't automatically the right one for you. DSIP is not a like-for-like substitute. It's a research peptide with a genuinely interesting but old and thin human data set, no FDA pathway, and no standardized human dosing. Where DSIP fits is in the research and self-experimentation space, ideally approached the way DSIP Peptide covers it: provider-reviewed, sourced with purity documentation, and with expectations calibrated to what 1970s-90s pilot studies actually showed rather than what a supplement blurb implies. If you go that route, do it through a provider-reviewed source and a pharmacy partner that can speak to compounding and purity standards, not a random storefront.

Frequently asked questions

Is DSIP as effective as trazodone for insomnia?

There's no direct human trial comparing them, so nobody can say definitively. Trazodone has more recent, larger human insomnia data (e.g., Roth et al. 2011) ^[5], while DSIP's human sleep data is small, old (mostly 1970s-90s), and mixed. Trazodone has the stronger, more current evidence base, though even its insomnia efficacy data is debated.

Can I take DSIP and trazodone together?

There's no published human interaction data because DSIP hasn't been studied alongside trazodone in controlled trials. Combining an unapproved research peptide with a prescription antidepressant without physician oversight is not something to do without medical guidance, given trazodone's known interaction risks with other CNS-active compounds.

Is DSIP FDA-approved like trazodone?

No. Trazodone was FDA-approved in 1981 for major depressive disorder ^[1]. DSIP has never gone through FDA approval for any indication and is sold as a research chemical, not a regulated drug.

Why do people compare DSIP to trazodone at all?

Both get discussed as sleep aids outside their approved use: trazodone is prescribed off-label for insomnia, and DSIP was originally researched decades ago specifically for sleep induction. The comparison makes sense as a framing device, but the evidence quality behind each is very different.

Does trazodone cause weight gain or grogginess the way some peptides claim to avoid?

Trazodone commonly causes next-day sedation and grogginess, especially at higher doses, and some patients report weight changes, though this varies by individual. DSIP's modern side effect profile in humans isn't well characterized enough to make a confident comparison either way.

What's the actual mechanism difference between DSIP and trazodone?

Trazodone is a serotonin antagonist and reuptake inhibitor that also blocks histamine H1 receptors, contributing to sedation; this is documented in human pharmacology studies tied to its depression approval. DSIP's mechanism in humans is still not well characterized, per the Graf and Kastin 1986 review ^[4].

Is DSIP legal to buy in the US?

DSIP is generally sold labeled for research use only, not for human consumption, and isn't a scheduled controlled substance. That's different from being an approved medical treatment; no prescriber can legally prescribe it for insomnia, and no clinical monitoring structure exists around its use the way it does for trazodone.

What dose of trazodone is used for sleep versus depression?

Off-label insomnia dosing is typically 25-100mg at bedtime, well under the 150-400mg+ range used for depression ^[6]. Exact dose depends on the prescriber's judgment and patient response; there's no FDA-set insomnia dose because trazodone isn't approved for that use.

Has anyone run a modern controlled trial of DSIP for sleep?

Not that meets current standards. The human DSIP literature is concentrated in the late 1970s through early 1990s, with small samples and inconsistent polysomnography results ^[3][4]. No large, modern, placebo-controlled trial using current sleep-lab standards has been published.

Does DSIP lower cortisol like some sources claim?

The cortisol and ACTH-modulation findings mostly come from animal studies (rats, rabbits), not controlled human trials. It's a real preclinical finding, but presenting it as an established human effect overstates what the data shows.

Which has more documented side effects, DSIP or trazodone?

Trazodone, by far, simply because it has been used in millions of patients for over 40 years, giving a well-characterized profile including sedation, dizziness, dry mouth, and rare priapism. DSIP's human safety data is too sparse and old to build a comparable profile.

Can a doctor prescribe DSIP instead of trazodone?

No. DSIP isn't an approved pharmaceutical, so it has no prescribing pathway. A doctor can prescribe trazodone off-label for insomnia after an evaluation, but DSIP falls outside that system entirely and is accessed through research chemical suppliers instead.

Sources

1. FDA, Desyrel (trazodone hydrochloride) approval history: Trazodone was FDA-approved (as Desyrel) for major depressive disorder in 1981
2. NCBI PubMed, isolation and characterization of DSIP: DSIP was first isolated from rabbit brain venous blood in the 1970s
3. PubMed, Schneider-Helmert DSIP sleep disturbance study: DSIP administration in patients with chronic sleep disturbance showed inconsistent objective polysomnography effects despite subjective improvement
4. PubMed, Graf and Kastin review of DSIP literature: DSIP effects on sleep were variable across studies and its mechanism was not well understood as of the 1986 review
5. PubMed, Roth et al. trazodone insomnia trial: Trazodone 50mg showed modest improvements in subjective and polysomnographic sleep measures in a placebo-controlled trial
6. PubMed, Mendelson review of trazodone for insomnia: Trazodone is used extensively off-label for insomnia despite limited placebo-controlled efficacy evidence